Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.44 SEK | +2.99% | +26.94% | -55.09% |
May. 30 | Oncopeptides Issues Warrants Under Loan Deal with European Investment Bank | MT |
May. 30 | Transcript : Oncopeptides AB, Q1 2024 Earnings Call, May 30, 2024 |
Sales 2024 * | 84.16M 8.11M | Sales 2025 * | 199M 19.19M | Capitalization | 740M 71.33M |
---|---|---|---|---|---|
Net income 2024 * | -241M -23.22M | Net income 2025 * | -172M -16.57M | EV / Sales 2024 * | 6.82 x |
Net cash position 2024 * | 166M 16.02M | Net cash position 2025 * | 71.92M 6.93M | EV / Sales 2025 * | 3.36 x |
P/E ratio 2024 * |
-1.69
x | P/E ratio 2025 * |
-3.18
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.37% |
Latest transcript on Oncopeptides AB
1 day | +2.99% | ||
1 week | +26.94% | ||
Current month | +7.50% | ||
1 month | +15.44% | ||
3 months | -45.74% | ||
6 months | -59.38% | ||
Current year | -55.09% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 3.44 | +2.99% | 5,239,128 |
24-06-04 | 3.34 | +4.70% | 6,994,542 |
24-06-03 | 3.19 | -0.31% | 1,688,452 |
24-05-31 | 3.2 | +10.54% | 3,648,081 |
24-05-30 | 2.895 | +6.83% | 8,189,789 |
Delayed Quote Nasdaq Stockholm, June 05, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.09% | 71.03M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.57% | 22.67B | |
-9.56% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- ONCO Stock